For the roughly half of high-risk localized prostate cancer patients who relapse within five years of surgery, perioperative intensification of androgen blockade has long been an appealing but unproven strategy. This large Phase 3 randomized controlled trial now provides the most rigorous evidence to date that adding the next-generation androgen receptor inhibitor apalutamide to standard androgen-deprivation therapy around the time of radical prostatectomy meaningfully shifts pathological outcomes.
The NEJM-published trial enrolled 2,109 patients with newly diagnosed high-risk localized or locally advanced prostate cancer, randomizing them 1:1 to ADT plus apalutamide (240 mg/day) or ADT plus placebo across six 28-day cycles bracketing radical prostatectomy with pelvic lymph-node dissection. After a median follow-up of nearly 62 months, pathological complete response or minimal residual disease — defined as pathological stage ypT2 or lower with tumor burden ≤5 mm — occurred in 8.9% of the apalutamide arm versus just 1.0% in the placebo arm, yielding an odds ratio of approximately 10.17. Dual primary endpoints also included metastasis-free survival assessed by both conventional imaging and PSMA-PET, with full survival data anchoring the clinical relevance of the pathological signal.
This is a potentially practice-changing finding. Apalutamide, already approved for metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer, now demonstrates meaningful neoadjuvant and adjuvant activity in the curative-intent setting. The tenfold improvement in complete pathological response is striking, though absolute rates remain modest — 8.9% versus 1.0% — underscoring that most patients still have residual disease even with intensified treatment. The critical question, not yet fully answered here, is whether this pathological surrogate translates into durable improvements in overall survival, a bar that has historically been difficult to clear in the perioperative prostate cancer space. Toxicity and quality-of-life data will also be essential for shared decision-making, given the extended ADT exposure. Overall, this trial represents a significant incremental advance and a strong rationale for reconsidering perioperative treatment standards in high-risk disease.